Idiopathic Pulmonary Fibrosis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type (Pirfenidone, Nintedanib, others), By Route of Administration (Parenteral, Oral, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 3.88 Billion
CAGR (2026-2031)	6.71%
Fastest Growing Segment	Pirfenidone
Largest Market	North America
Market Size (2031)	USD 5.73 Billion

Market Overview

The Global Idiopathic Pulmonary Fibrosis Market will grow from USD 3.88 Billion in 2025 to USD 5.73 Billion by 2031 at a 6.71% CAGR. Idiopathic Pulmonary Fibrosis (IPF) therapeutics encompass antifibrotic agents and adjunctive interventions designed to mitigate the progression of irreversible lung scarring and preserve respiratory function in patients. The market’s expansion is fundamentally supported by an aging global demographic, as the disease incidence correlates strongly with advanced age, alongside improvements in high-resolution imaging that facilitate earlier and more accurate clinical detection. According to the Pulmonary Fibrosis Foundation, in 2024, pulmonary fibrosis and interstitial lung diseases impact over 250,000 Americans, with approximately 50,000 individuals newly diagnosed each year.

Despite these growth drivers, a significant challenge impeding market expansion is the prohibitive cost of long-term antifibrotic therapy, which restricts patient access in healthcare systems with stringent reimbursement policies. This economic barrier, often exacerbated by rigorous payer criteria for approval, limits the widespread adoption of these essential life-prolonging treatments in both developed and emerging markets.

Key Market Drivers

The increasing prevalence of Idiopathic Pulmonary Fibrosis (IPF) stands as a primary determinant of market trajectory, necessitating a proportional expansion in therapeutic availability and patient support systems. As diagnostic capabilities improve, healthcare providers are identifying more cases of this chronic, progressive lung disease, which directly escalates the demand for long-term management solutions. This rising disease burden is not limited to a single region but represents a growing global health challenge that fuels the commercial necessity for effective treatments. According to the Canadian Pulmonary Fibrosis Foundation, September 2024, in the 'Hope Breathes Here Press Release', approximately 30,000 Canadians are currently living with pulmonary fibrosis, reflecting the significant and expanding patient pool requiring medical intervention.

Concurrently, the accelerated adoption of advanced antifibrotic therapies drives substantial market value, as these drugs remain the standard of care for slowing disease progression. The commercial success of established agents encourages sustained research and development, creating a competitive environment where efficacy and safety are paramount. This robust demand for effective pharmaceutical interventions is evidenced by the financial performance of leading therapeutics; according to Boehringer Ingelheim, April 2024, in the 'Annual Report 2023', net sales for their fibrosis portfolio, driven primarily by Ofev, reached 3.5 billion EUR. Beyond current sales, the market is characterized by active capital flow into future innovations. According to Vicore Pharma, in 2024, the company successfully completed a rights issue raising approximately 782 million SEK to advance their lead candidate through clinical trials.

Download Free Sample Report

Key Market Challenges

The prohibitive cost of long-term antifibrotic therapy stands as a significant economic barrier impeding the growth of the Global Idiopathic Pulmonary Fibrosis (IPF) Market. These essential medications, while effective in slowing disease progression, carry high price tags that often exceed the financial reach of patients and healthcare systems alike. Consequently, payers and insurance providers frequently implement stringent reimbursement criteria, such as requiring documented decline in lung function before authorizing treatment. This delays therapy initiation and restricts the addressable patient population, directly reducing market revenue potential.

This financial toxicity not only limits new patient uptake but also drives high rates of treatment discontinuation. Patients facing substantial out-of-pocket expenses are often forced to prioritize basic living costs over medication adherence, leading to suboptimal clinical outcomes and reduced volume of drug sales. According to the Pulmonary Fibrosis Foundation, in 2024, Medicare beneficiaries in the United States faced an annual out-of-pocket spending limit of approximately $8,000 for prescription drugs before new caps were introduced, illustrating the severe financial burden placed on the elderly demographic most affected by the disease. Such economic pressures create a restrictive environment that dampens the widespread adoption of therapeutics, thereby hampering the overall expansion of the global market.

Key Market Trends

Integration of Artificial Intelligence in Diagnostic Imaging is fundamentally altering the Global Idiopathic Pulmonary Fibrosis Market by replacing subjective manual assessments with automated, quantitative biomarkers that predict disease trajectory with greater accuracy. These AI-driven tools analyze computed tomography scans to quantify lung structure variations, providing clinicians with robust data to stratify patients for clinical trials and personalized treatment plans. According to the National Institutes of Health, March 2025, in the 'ERS Congress 2024: highlights from the Interstitial Lung Diseases Assembly' report, the AI-calculated Weighted Reticulovascular Score (WRVS) demonstrated superior prognostic capability compared to traditional densitometry, identifying patients at high risk of mortality with a hazard ratio of 4.55.

The Emergence of Next-Generation Mechanism-Specific Therapies represents a pivotal shift away from broad-spectrum antifibrotics toward precision agents targeting distinct pathogenic pathways such as lysophosphatidic acid signaling. This trend is driven by the urgent need to improve patient adherence and outcomes through drugs that offer better safety profiles and targeted efficacy than legacy treatments like pirfenidone and nintedanib. According to Chest Physician, July 2025, in the article 'Admilparant phase 2 results raise hopes for combination treatment in pulmonary fibrosis', the investigational LPA1 antagonist admilparant achieved a 54% relative risk reduction in the rate of lung function decline among patients with idiopathic pulmonary fibrosis receiving the 60 mg dosage.

Segmental Insights

The Pirfenidone segment is currently recognized as the fastest-growing category within the Global Idiopathic Pulmonary Fibrosis Market. This accelerated expansion is primarily driven by the expiration of key patents, which has facilitated the introduction of cost-effective generic formulations, thereby significantly improving treatment affordability and accessibility for a broader patient population. Furthermore, the drug’s established efficacy in slowing the decline of lung function continues to secure high prescription rates from healthcare providers. Ongoing oversight and approvals by regulatory bodies, such as the U.S. Food and Drug Administration, further reinforce provider confidence and support the segment's rapid upward trajectory.

Regional Insights

North America maintains a leading position in the Global Idiopathic Pulmonary Fibrosis market, driven primarily by high diagnosis rates and a robust healthcare infrastructure. The region benefits significantly from extensive research and development activities conducted by major pharmaceutical companies based in the United States. Additionally, supportive regulatory frameworks provided by the United States Food and Drug Administration, including orphan drug incentives, accelerate the approval of novel therapies. Comprehensive reimbursement coverage for high-cost fibrotic disease treatments further ensures market expansion, making North America the central hub for industry revenue and clinical advancements.

Recent Developments

• In October 2025, Boehringer Ingelheim announced that the U.S. Food and Drug Administration approved its new therapeutic, nerandomilast, for the treatment of adults with idiopathic pulmonary fibrosis. Marketed under the brand name Jascayd, the oral medication became the first new treatment class approved for this condition in over a decade. The regulatory decision was supported by data from the global FIBRONEER-IPF Phase 3 trial, which demonstrated the drug's ability to significantly slow the decline in lung function compared to placebo. This approval introduced a novel phosphodiesterase 4B inhibitor to the market, addressing a critical unmet need for patients with progressive fibrosing lung disease.
• In September 2025, United Therapeutics announced that its Phase 3 TETON-2 study evaluating nebulized Tyvaso in patients with idiopathic pulmonary fibrosis met its primary efficacy endpoint. The pivotal trial demonstrated a statistically significant improvement in absolute forced vital capacity compared to placebo after 52 weeks of treatment. The study also achieved key secondary endpoints, including improvements in quality of life metrics and a reduction in the time to clinical worsening. Based on these positive results, the company disclosed its intention to submit a supplemental New Drug Application to regulatory authorities, aiming to expand the label of the inhaled prostacyclin mimetic to include this fibrosis indication.
• In September 2024, Insilico Medicine released encouraging preliminary data from a Phase 2a clinical trial evaluating ISM001-055 in patients with idiopathic pulmonary fibrosis. The study assessed the safety and efficacy of the small molecule inhibitor, which was notably discovered and designed using the company's generative artificial intelligence platform. Clinical results indicated that the drug met its primary safety endpoints and demonstrated a dose-dependent improvement in forced vital capacity over a 12-week treatment period. This outcome highlighted the potential of AI-driven drug discovery to deliver effective therapeutic candidates for fibrotic lung diseases, validating the research approach in a clinical setting.
• In May 2024, Endeavor BioMedicines announced favorable outcomes from a Phase 2a clinical trial evaluating ENV-101 for the treatment of idiopathic pulmonary fibrosis. The study demonstrated that the novel Hedgehog signaling pathway inhibitor significantly improved lung function and reduced fibrosis in participants over the trial period. Results indicated that the therapeutic agent was well-tolerated and capable of potentially reversing key indicators of the disease, distinguishing it from existing standards of care that primarily slow progression. Following these promising findings, the company outlined strategic plans to advance the drug into a Phase 2b study to further assess its efficacy in a broader patient population.

Key Market Players

• Boehringer Ingelheim International GmbH
• F. Hoffmann-La Roche Ltd.
• Cipla Limited
• Shionogi & Co., Ltd
• Bristol-Myers Squibb Company
• United Therapeutics Corporation
• FibroGen, Inc
• Pliant Therapeutics, Inc
• Galecto, Inc.
• CSL Behring

By Drug Type	By Route of Administration	By Distribution Channel	By Region
Pirfenidone Nintedanib others	Parenteral Oral Others	Hospital Pharmacies Retail Pharmacies Online Pharmacies	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Idiopathic Pulmonary Fibrosis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Idiopathic Pulmonary Fibrosis Market , By Drug Type:

• Pirfenidone
• Nintedanib
• others

• Idiopathic Pulmonary Fibrosis Market , By Route of Administration:

• Parenteral
• Oral
• Others

• Idiopathic Pulmonary Fibrosis Market , By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

• Idiopathic Pulmonary Fibrosis Market , By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE